ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 38 of 45
Up
JMBS 2018, 3(3): 214–220
https://doi.org/10.26693/jmbs03.03.214
Medicine. Reviews

Modern Biochemical Aspects of Xenobiotic Detoxification System. Literature Review

Stetsenko S. O., Bondareva A. V.
Abstract

Foreign chemicals that are usually considered as "xenobiotics" are commonly used environmental factors, which can have a negative impact on the body. It is proved that most xenobiotics do not have a direct biological effect due to their previous biotransformation (metabolism). The process of biotransformation is based mainly on the xenobiotics detoxification, which is why it is considered to be one of the protective and adaptive mechanisms. Violation of biochemical mechanisms of xenobiotics detoxification is one of the reasons for the imbalance of homeostasis and the development of pathological processes. The process of xenobiotics detoxification consists of three phases: activation, neutralization and excretion from the body. The combined action of the first two phases usually leads to increased hydrophilicity and decreased activity and toxicity of xenobiotics. The most important link in the first phase of xenobiotics detoxification is the monooxygenase system, which is localized in the membranes of the endoplasmic reticulum and is represented by cytochromes P450 and b5, NADH and NADH reductases. The first phase is based primarily on oxidative transformations involving enzymes of cytochrome P-450 families, flavin-dependent monooxygenase, alcohol dehydrogenase, aldehyde dehydrogenase, prostaglandin synthase. In this phase there may also occur hydrolysis reactions with the participation of arylstearase, carboxyletherase. Increasing the xenobiotics polarity decreases their lipophilicity and greatly enhances the possibility of excretion. The second phase of xenobiotics detoxification, the conjugation phase, is also aimed at increasing hydrophilicity and reducing the toxicity of the xenobiotics due to the action of mainly enzymes of transferases class: glutathione transferase, UDP-glucuronyltransferase, arylamine-N-acetyltransferase, sulfotransferase, acetyltransferase, methyltransferase. The effectiveness of the xenobiotics detoxification system is due to the individual genetic features of the organism, which determine the differential individual’s sensitivity to environmental factors in the form of compensatory-adaptive reactions. The third phase of xenobiotics detoxification ensures the detoxification products excretion from the body through the lungs, kidneys, gastrointestinal tract. Xenobiotics with significant hydrophobicity and molecular weight are excreted with bile. There are various mechanisms for the conjugates elimination from the body: through the ATP-dependent ion pump, with the participation of highly specific transporters of organic anions and dinitrophenol conjugates of glutathione, P-glycoprotein and a number of proteins that can cause multiple resistance to xenobiotics. The above-mentioned analytical review of literature on general ideas about the process of xenobiotics detoxification in the human body and animals does not claim to be its complete coverage. The theoretical generalizations, which are given above and scientific approaches should be taken into account when studying the biochemical mechanisms of neutralization xenobiotics processes violations and the development of means for their correction.

Keywords: xenobiotics, detoxification, activation, neutralization, excretion

Full text: PDF (Ukr) 216K

References
  1. Gerych OKh, Pentyuk OO. Vplyv perevantazhennya ratsionu zhyramy na enzymatychni systemy metabolizmu u shchuriv. Ukr biokhimichnyy zhurnal. 2008; 80 (1): 73-82. [Ukrainian]
  2. Zharyn VA, Fedorovych SV, Markova AG. Polymorfyzm genov byotransformatsyy ksenobyotykov. Voennaya medytsyna. 2013; 3: 122-4. [Russian]
  3. Krzhechkovskaya VV. Membranosvyazannyy tsytokhrom V5. Rol tsytokhroma V5 v regulyatsyy aktyvnosty yzoform tsytokhroma R-450. Krytycheskye tekhnology. Membrany. 2005; 2 (26): 10-22. [Russian]
  4. Kulynskyy VY. Obezvrezhyvanye ksenobyotykov. Sorovskyy obrazovatelnyy zhurnal. 1999; 1: 8-12. [Russian]
  5. Marchenko MM, Ketsa OV, Velykyy MM. Biokhimichna transformatsiya ksenobiotykiv u organizmi. Chernivtsi: Chernivetskyy nats un-t, 2011. 280 s. [Ukrainian]
  6. Padalko VY, Sevastyanova TV. Klynycheskye aspekty funktsyonyrovanyya systemy tsytokhroma R450 mykrosom pecheny. Visnyk Kharkivskogo natsionalnogo universytetu im VN Karazina. 2005; 705 (11): 110-21. [Russian]
  7. Stolyar OB, Kalinina IV, Yukalo VG. Ksenobiotyky: nakopychennya, detoksykatsiya ta vyvedennya z zhyvykh organizmiv. Ternopil: Vydavnytstvo TNTU im I Pulyuya, 2012. 384 s. [Ukrainian]
  8. Chernyak YuY, Kolesnykov SY, Chernyak EV. Tsytokhrom R450: osnovnye predstavlenyya, metody yssledovanyya, znachenye dlya praktycheskoy medytsyny. Yrkutsk: Yzd-vo YGU, 2014. 47 s. [Russian]
  9. Anzenbacher P, Zanger UM. Anzenbacher P. Metabolism of drugs and other xenobiotics. Wiley-VCH, 2012. 724 p. https://doi.org/10.1002/9783527630905
  10. Abraham NG, Levere RD, Freedman ML. Effect of age on rat liver heme and drug metabolism. Exp Gerontol. 1985; 20: 277-84. https://www.ncbi.nlm.nih.gov/pubmed/3841517. https://doi.org/10.1016/0531-5565(85)90053-1
  11. Amacher DE. The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol Mech Methods. 2010; 20 (4): 159-66. https://www.ncbi.nlm.nih.gov/pubmed/20218941. https://doi.org/10.3109/15376511003690307
  12. Buehler CJ, Urlacher VB. A novel P450-based biocatalyst for the selective production of chiral 2-alkanols. Chem Commun. 2014: 50: 4089-91. https://doi.org/10.1039/c4cc00647j
  13. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today. 2001; 6: 835-9. https://doi.org/10.1016/S1359-6446(01)01892-X
  14. McGill MR, Du K, Weemhoff JL, Jaeschke H. Critical review of resveratrol in xenobiotic-induced hepatotoxicity. Food Chem Toxicol. 2015; 10 (86): 309-18. https://www.ncbi.nlm.nih.gov/pubmed/26561740. https://www.ncbi.nlm.nih.gov/pmc/articles/4710062. https://doi.org/10.1016/j.fct.2015.11.003
  15. Hohl M, Briand C, Grutter MG, Seeger MA. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nature Str Mol Biol. 2012; 19: 395-402. https://www.ncbi.nlm.nih.gov/pubmed/22447242. https://doi.org/10.1038/nsmb.2267
  16. Danielle K, Pelkonen O, Ahokas T. Hepatocytes: the powerhouse of biotransformation. Int J Biochem Cell Biol. 2012; 44: 257-65. https://doi.org/10.1016/j.biocel.2011.11.011
  17. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomedical Papers. 2010; 154 (2): 103-16. https://www.ncbi.nlm.nih.gov/pubmed/20668491. https://doi.org/10.5507/bp.2010.017
  18. Juchau M, Boutelet-Bochan H, Huang Y. Cytochrome P-450-dependent biotransformation of xenobiotics in human and rodend embrionic tissues. Drug Metab Rev. 1998; 30 (3): 541-68. https://www.ncbi.nlm.nih.gov/pubmed/9710705. https://doi.org/10.3109/03602539808996324
  19. Kodama S, Negishi M. Sulfotransferase genes: regulation by nuclear receptors in response to xeno/endobiotics. Drug Metabolism Reviews. 2013; 45 (4): 441-9. https://www.ncbi.nlm.nih.gov/pubmed/24025090. https://www.ncbi.nlm.nih.gov/pmc/articles/4049416. https://doi.org/10.3109/03602532.2013.835630
  20. Lamb DC, Waterman MR. Unusual properties of the cytochrome P450 superfamily. Phil Trans R Soc Lond B Biol Sci. 2013; 368 (1612): 20120434. https://www.ncbi.nlm.nih.gov/pubmed/23297356. https://www.ncbi.nlm.nih.gov/pmc/articles/3538423. https://doi.org/10.1098/rstb.2012.0434
  21. Li Z, Langhans SA. Transcriptional regulators of Na,K-ATPase subunits. Front Cell Dev Biol. 2015; 3: 66-75. https://doi.org/10.3389/fcell.2015.00066
  22. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics. 2002; 3 (3): 349-66. https://www.ncbi.nlm.nih.gov/pubmed/12052143. https://doi.org/10.1517/14622416.3.3.349
  23. Niwa T, Murayama N, Yamazaki H. Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome P450. Current Drug Metabolism. 2016; 17 (Iss 7): 700-12. https://www.ncbi.nlm.nih.gov/pubmed/19594405
  24. Ortiz de Montellano PR. Cytochrome P450-activated prodrugs. Future Med Chem. 2013; 5: 213-28. https://www.ncbi.nlm.nih.gov/pubmed/23360144. https://www.ncbi.nlm.nih.gov/pmc/articles/3697796. https://doi.org/10.4155/fmc.12.197
  25. Maity S, Rajkumar A, Matai L, Bhat A, Ghosh A, Agam G, Kaur S, Bhatt NR, et al. Oxidative homeostasis regulates the response to reductive endoplasmic reticulum stress through translation control. Cell Reports. 2016; 16: 851-65. https://www.ncbi.nlm.nih.gov/pubmed/27373166. https://doi.org/10.1016/j.celrep.2016.06.025
  26. Pande JN, Pande A, Singh SP. Acetylator status, drug metabolism and disease. Natl Med J India. 2003; 16 (1): 24-6. https://www.ncbi.nlm.nih.gov/pubmed/12715953
  27. Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. International Journal of Biochemistry and Cell Biology. 2013; 45 (6): 1121-32. https://www.ncbi.nlm.nih.gov/pubmed/23500526. https://doi.org/10.1016/j.biocel.2013.02.019.
  28. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Eur J Physiol. 2000; 440: 337-50. https://www.ncbi.nlm.nih.gov/pubmed/10954321. https://doi.org/10.1007/s004240000297
  29. Samhan-Arias AK, Gutierrez-Merino C. Purified NADH-cytochrome b5 reductase is a novel superoxide anion source inhibited by apocynin: sensitivity to nitric oxide and peroxynitrite. Free Radic Biol Med. 2014; 73: 174-89. https://www.ncbi.nlm.nih.gov/pubmed/24816293. https://doi.org/10.1016/j.freeradbiomed.2014.04.033
  30. Schenkman JB, Jansson I. The many roles of cytochrome b5. Pharmacol Ther. 2003; 97 (2): 139-52. https://www.ncbi.nlm.nih.gov/pubmed/12559387. https://doi.org/10.1016/S0163-7258(02)00327-3